Japanese encephalitis virus is an RNA flavivirus that causes virus encephalitis across Asia, the western Pacific region and parts of Australia.
It is transmitted in an enzootic cycle and the virus is transmitted to humans through the bite of infected Culex tritaeniorhynchus mosquitoes.
There is no specific antiviral treatment for Japanese encephalitis virus and management is mainly symptomatic treatment and supportive care.
Personal protection from mosquito bites in endemic areas and obtaining vaccination are the primary strategies to control Japanese encephalitis virus infection due to lack of specific antiviral therapy, high case fatality, and substantial morbidity.
Pharmacological management of vascular cognitive impairment (VCI) is a balancing act when it comes to the use of antihypertensives, statins and oral anticoagulants (OACs), according to Professor Majon Muller of the Department of Internal Medicine, Amsterdam University Medical Center, the Netherlands, who spoke at VasCog 2018 held in Hong Kong.
Early detection, intervention and adoption of a healthy lifestyle are the key to ending dementia, according to Professor Vincent Mok of the Division of Neurology, Faculty of Medicine, Chinese University of Hong Kong.